An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having C<SUB>max</SUB> to C<SUB>min</SUB> ratio less than 200 and lag time less than 0.2.
